Long-term follow-up data from cardiovascular outcomes trials indicate that any early increase in retinopathy events tends to plateau over time, and the overall trajectory of retinal health may ultimately be favorable due to sustained improvements in glycemic control
for example, highest-risk members in tier 1 could be covered with a $0 copay, while slightly lower-risk members in tier 3 could have some coverage but a greater copay
GLP-1 medications offer real benefits for weight and blood sugar management but those benefits should not come at the cost of bone density, muscle function, or immune health
The bottom line on side effects: Retatrutide is not dramatically riskier for most people, but it is not a simple lateral move
User further understands and agrees that these products are not supplements, health or nutrition alternatives, additives, or products